Abstract. Alzheimer's disease, one of the most important brain pathologies associated with neurodegenerative processes, is related to overactivation of calpain-mediated proteolysis. Previous data showed a compelling efficacy of calpain inhibition against abnormal synaptic plasticity and memory produced by the excess of amyloid-␤, a distinctive marker of the disease. Moreover, a beneficial effect of calpain inhibitors in Alzheimer's disease is predictable by the occurrence of calpain hyperactivation leading to impairment of memory-related pathways following abnormal calcium influxes that might ensue independently of amyloid-␤ elevation. However, molecules currently available as effective calpain inhibitors lack adequate selectivity. This work is aimed at characterizing the efficacy of a novel class of epoxide-based inhibitors, synthesized to display improved selectivity and potency towards calpain 1 compared to the prototype epoxide-based generic calpain inhibitor E64. Both functional and preliminary toxicological investigations proved the efficacy, potency, and safety of the novel and selective calpain inhibitors NYC438 and NYC488 as possible therapeutics against the disease. 
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Quantification was achieved by the internal stan-234 dard method using peak area ratios of the analyte to IS in plasma for NYC215 and NYC438.
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For NYC488, external standard method was used.
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Concentrations were calculated using a weighted 238 least-squares linear regression (W = 1/x 2 ). The assay 239 was performed using an LC/MS/MS system con- Fig. 1. Chemical structure of the prototype epoxide compound E64. The structure of E64 can be functionally divided into three main domains: the epoxidic warhead that interacts with an enzymatic pocket of calpains producing the protease inhibition, a peptidomimetic leucin domain P2 that it is important to modulate the selectivity of any derivative compound for calpains, and finally a P3 compound cap that is useful for druggability development and for improving the pharmacological potency. min) onto LTP in vitro when co-administered at 650 nM, the ED50 for E64. Compounds are grouped according to the progressive optimization throughout the drug discovery process: 1st generation compounds (1st Gen) are compounds with potency equal or slightly higher versus E64; 2nd generation compounds (2nd Gen) have higher potency than E64 in inhibiting calpain; and 3rd generation (3rd Gen) compounds, instead, are more potent than E64 displaying improved selectivity toward calpain 1 inhibition. Fig. 3 . Analysis of drug kinetics in plasma. The analysis of kinetics indicates that all three candidate compounds NYC215 (7.57 mg/kg), NYC438 (7.86 mg/kg), and NYC488 (7.83 mg/kg) are rapidly absorbed upon i.p. injection. The peak plasma concentration occurred at 0.25, 0.5, and 0.125 h after dosing, respectively. Their half-life was ∼0.6 h, ∼1.1 h, and ∼0.6 h, respectively. The new calpain inhibitors were effective in decreasing the spectrin fragment at around 145 kDa that is generated specifically by calpain. The decrease of the specific calpain-generated fragment demonstrates that the drugs can reach the brain upon systemic administration, overcoming the problems related to first-pass metabolism and blood-brain barrier penetration.
pounds NYC438 and NYC488 dramatically reduced 464 the amount of fragments (Fig. 4) (Fig. 5D ). Table 1 Assessment of the toxicity profile of new calpain inhibitors in vivo. Compounds NYC215, NYC438, and NYC488 were chronically administered in vivo at the respective MTDs (that are over 10 times higher than the expected therapeutic dose). Histological evaluation for probing gross modifications were carried out in different target organs known to be a possible source of concern in epoxide-based and/or calpain inhibition treatments (liver, kidney, muscle, stomach, and brain). The 3rd generation compounds NYC438 and NYC488 showed no sign of toxicity whereas the 2nd generation compound NYC215 induced a discrete isometric tubular epithelial vacuolization in the kidney, probably associated to osmolarity adjustment (Fig. 6B) . The novel calpain inhibitors 631 were able to prevent the cognitive disturbance Daily treatment with NYC215, NYC438 and NYC488 from the age of 2 months until 7 months ameliorated the defect in contextual fear memory. WT-vehicle: n = 18, WT-NYC215: n = 9, WT-NYC438: n = 9, WT-NYC488: n = 9, A␤PP/PS1-vehicle: n = 17; A␤PP/PS1-NYC215: n = 10; A␤PP/PS1-NYC438: n = 10; A␤PP/PS1-NYC488: n = 11. p < 0.05 in all transgenic groups treated with compound compared to their respective vehicle-treated transgenics. C) Daily treatment with NYC215, NYC438, and NYC488 from the age of 2 months until 3 months ameliorated the defect in spatial memory in A␤PP/PS1 mice. WT-vehicle: n = 15, WT-NYC215: n = 8, WT-NYC438: n = 8, WT-NYC488: n = 8, A␤PP/PS1-vehicle: n = 15, A␤PP/PS1-NYC215: n = 10, A␤PP/PS1-NYC438: n = 11, A␤PP/PS1-NYC488: n = 10. p < 0.05 in all transgenic groups treated with compound compared to their respective vehicle-treated transgenics. D) Daily treatment with NYC215, NYC438, and NYC488 from the age of 2 months until 7 months ameliorated the defect in spatial memory in A␤PP/PS1 mice. WT-vehicle: n = 18, WT-NYC215: n = 9, WT-NYC438: n = 9, WT-NYC488: n = 9, A␤PP/PS1-vehicle: n = 17; A␤PP/PS1-NYC215: n = 10; A␤PP/PS1-NYC438: n = 10; A␤PP/PS1-NYC488: n = 11. p < 0.05 in all transgenic groups treated with compound compared to their respective vehicle-treated transgenics.
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Taken together, these data suggest that the novel 
